Roche/Genentech is the most biologically sophisticated target in our series. The vast majority of Roche's top-revenue drugs are monoclonal antibodies — Ocrevus, Hemlibra, Tecentriq, Perjeta, Herceptin, Kadcyla, Phesgo, Xolair, Polivy, Columvi, Lunsumio — none of which are P-gp/BCRP substrates. However, Roche has several small-molecule assets where the opportunity is exceptional, and one of the most compelling combinations in our entire four-company analysis.
The lead recommendation is Itovebi (inavolisib) + Elacridar for PIK3CA-mutated breast cancer brain metastases. This rests on a remarkable foundation: inavolisib's October 2024 FDA prescribing label explicitly confirms it is a P-glycoprotein and BCRP substrate. Breast cancer brain metastases are highly enriched for PIK3CA mutations (30.8% vs 17.1% in patients without brain metastases). The BBB efflux of inavolisib is the primary pharmacological barrier preventing Roche's already-approved PI3Ka inhibitor from being effective in the CNS compartment where PIK3CA-mutated tumours frequently spread. Elacridar co-administration unlocks a CNS indication for inavolisib that no other PI3K inhibitor has credibly addressed.
A strong secondary programme exists around Roche's pipeline BTK inhibitor fenebrutinib for progressive MS, where an elacridar-enabled formulation could optimise CSF exposure beyond the already-demonstrated "brain penetrant" label, potentially surpassing competitor CSF levels while retaining fenebrutinib's superior safety profile. The MMAE-payload ADC Polivy represents a third opportunity via intracellular P-gp resistance reversal in DLBCL.
The Roche Platform Play — Unique in Our Series: Roche Diagnostics is the global leader in companion diagnostics infrastructure. A platform deal with Roche could simultaneously: (1) license inavolisib + elacridar for breast cancer brain metastases; (2) co-develop the P-gp IHC/mRNA companion diagnostic for patient selection across all four company indications (not just Roche); and (3) leverage Roche's CNS translational infrastructure (MS, Alzheimer's, SMA) to build the BBB pharmacology clinical methods — CSF sampling, PET transporter imaging, CNS biomarker panels — needed to validate elacridar's mechanism in all combination Phase I studies. This makes a Roche deal potentially the cornerstone of our entire platform strategy.
| Drug (Brand) | Class / Indication | 2024 Sales | LOE | P-gp / BCRP Substrate? | Combination Rationale | Type | Score | Projected Combo Peak Sales |
|---|---|---|---|---|---|---|---|---|
| Ocrevus ocrelizumab |
Neurology — anti-CD20 mAb; relapsing and primary progressive MS | CHF 6.7bn | EU 2028; US 2029–2030 | Monoclonal antibody — not a P-gp/BCRP substrate | No pharmacological rationale. Ocrevus LOE creates urgency for Roche to differentiate the next MS asset — which is where fenebrutinib + elacridar becomes even more commercially compelling as a replacement franchise | N/A | LOW | No direct opportunity; strategic relevance to fenebrutinib timing |
| Evrysdi risdiplam |
Neurology — SMN2 RNA splicing modifier; spinal muscular atrophy | CHF 1.6bn | ~2033+ | Risdiplam was specifically engineered for excellent CNS penetration — it was designed to cross the BBB as a core therapeutic requirement. Published PK data confirm high and systemic SMN protein induction including in the CNS without transporter intervention | No meaningful rationale. CNS penetration was a design priority achieved inherently. Note: risdiplam inhibits MATE1/MATE2-K; adding elacridar introduces DDI complexity without benefit | N/A | LOW | No opportunity |
| Enspryng satralizumab |
Neurology — anti-IL-6R mAb; NMOSD | ~CHF 200m | ~2032+ | Monoclonal antibody — not a P-gp substrate | No rationale | N/A | LOW | No opportunity |
| Perjeta pertuzumab |
Oncology — anti-HER2 mAb; HER2+ breast cancer | CHF 3.6bn | US biosimilar 2026; EU 2025 | Monoclonal antibody — not a P-gp substrate. Biosimilar competition already entered | No rationale. Biosimilar erosion makes combination investment unattractive | N/A | LOW | No opportunity (declining LOE asset) |
| Herceptin trastuzumab |
Oncology — anti-HER2 mAb; HER2+ breast and gastric cancer | CHF 1.38bn | Heavily biosimilar-eroded globally | mAb — not a P-gp substrate | No rationale. Declining biosimilar-eroded asset | N/A | LOW | No opportunity |
| Phesgo pertuzumab + trastuzumab SC |
Oncology — fixed-dose SC combination; HER2+ breast cancer | CHF 1.7bn | Follows Perjeta/Herceptin LOEs ~2026+ | SC biologic — not a P-gp substrate | No rationale | N/A | LOW | No opportunity |
| Kadcyla ado-trastuzumab emtansine |
Oncology — HER2-targeting ADC + DM1 payload; HER2+ breast cancer | CHF 2.0bn | ~2028+ | ADC with maytansinoid DM1 payload. After ADC internalisation and DM1 release intracellularly, P-gp can efflux the free cytotoxin before it kills the cell — a documented ADC resistance mechanism for maytansinoid ADCs | Elacridar could inhibit intracellular P-gp efflux of DM1 payload in P-gp-overexpressing HER2+ breast cancer cells that have become resistant to Kadcyla. Most clinically relevant in the adjuvant setting where Kadcyla is standard of care but 20–30% of patients relapse. A companion diagnostic (P-gp expression IHC) would identify the MDR-driven relapsing subgroup. Speculative but pharmacologically sound; in vitro combination data required first | EFFICACY UP | LOW | CHF 300–500m (Kadcyla-resistant HER2+ breast cancer; in vitro data needed) |
| Itovebi (Inavolisib) STAR STAR RG6114 |
Oncology — PI3Ka inhibitor; PIK3CA-mutated HR+/HER2- breast cancer (FDA-approved October 2024) | Pre-revenue (launched Oct 2024) | ~2033+ (new asset) | YES — CONFIRMED IN FDA PRESCRIBING LABEL. The Itovebi FDA Prescribing Information (NDA 219249, approved October 10, 2024) explicitly states: "Inavolisib is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP)." This is the highest possible level of transporter substrate confirmation — from the regulatory document of a drug approved just 18 months ago | STAR STAR LEAD PROGRAMME. PIK3CA mutations are significantly enriched in breast cancer brain metastases (30.8% with brain mets vs 17.1% without; P=0.005). Inavolisib is approved for exactly this PIK3CA-mutated population but cannot adequately penetrate the BBB due to P-gp/BCRP efflux at the blood-brain barrier. Elacridar co-administration would abolish BBB efflux and achieve therapeutic PI3Ka inhibition in CNS metastases. Preclinical data at ASCO 2025 confirms inavolisib reduced intracranial tumour size in breast cancer brain metastasis mouse models. Elacridar is the missing pharmacological key. No competing PI3K inhibitor (alpelisib, copanlisib) has demonstrated credible BBB penetration — alpelisib showed no significant brain distribution in intact-BBB preclinical models. Inavolisib's mutation-selective PI3Ka inhibition avoids the CNS psychiatric side effects that killed buparlisib (which had BBB penetration but pan-PI3K toxicity). The combination would: (1) create a new indication for an already-approved drug (breast cancer brain metastases); (2) address a patient population with median OS of 4–6 months and no approved targeted therapy; and (3) establish inavolisib as the only PI3K inhibitor with proven CNS activity | BOTH | HIGH | CHF 1.5–2.5bn (15,000–20,000 PIK3CA+ patients per year in US+EU with CNS disease; unmet need supports $200–250k/yr pricing; accelerated approval pathway on intracranial ORR) |
| Tecentriq atezolizumab |
Oncology/IO — anti-PD-L1 mAb; NSCLC, urothelial, breast cancer, HCC | CHF 3.6bn | US 2030; EU ~2028–2030 | Monoclonal antibody — not a P-gp substrate | No direct pharmacological rationale. Indirect strategic angle: inavolisib + elacridar in brain metastases could eventually be combined with Tecentriq SC for triple-combination CNS therapy — but this is framing rather than mechanism | N/A | LOW | No direct opportunity |
| Avastin bevacizumab |
Oncology — anti-VEGF mAb; CRC, NSCLC, glioblastoma, ovarian cancer | CHF 1.2bn | Biosimilar-eroded globally | mAb — not a P-gp substrate. Biosimilar erosion ongoing | No rationale | N/A | LOW | No opportunity (biosimilar-eroded) |
| Polivy polatuzumab vedotin |
Haematology — CD79b ADC + MMAE payload; DLBCL (1st and 2nd line) | CHF 1.1bn (+39%) | ~2032+ | ADC with MMAE (monomethyl auristatin E) payload. MMAE is a confirmed P-gp substrate — after ADC internalisation and linker cleavage, intracellular P-gp can efflux free MMAE out of tumour cells before it achieves lethal tubulin inhibition. This MDR mechanism is well-documented for auristatin-payload ADCs and represents a primary route of acquired ADC resistance | Elacridar co-administration could inhibit intracellular P-gp efflux of MMAE in P-gp-overexpressing DLBCL cells. Relevant to the ~30% of DLBCL patients who develop primary or acquired resistance to Polivy-based regimens. A companion diagnostic (P-gp IHC at progression) would identify the resistant subgroup for combination therapy. This creates a precision oncology combination for refractory DLBCL. Roche Diagnostics could develop and commercialise the companion test — a fully integrated Roche play | EFFICACY UP | MEDIUM | CHF 400–700m (Polivy-resistant DLBCL; companion dx selected; growing base as Polivy becomes standard of care) |
| Columvi glofitamab |
Haematology — CD3xCD20 bispecific; r/r DLBCL | CHF 172m | ~2034+ | Bispecific antibody — not a P-gp substrate | No rationale | N/A | LOW | No opportunity |
| Lunsumio mosunetuzumab |
Haematology — CD3xCD20 bispecific; r/r follicular lymphoma | CHF 71m | ~2034+ | Bispecific antibody — not a P-gp substrate | No rationale | N/A | LOW | No opportunity |
| Gazyva / Gazyvaro obinutuzumab |
Haematology/Immunology — anti-CD20 mAb; CLL, follicular lymphoma, lupus nephritis | CHF 910m | ~2028+ | Monoclonal antibody — not a P-gp substrate | No rationale | N/A | LOW | No opportunity |
| Hemlibra emicizumab |
Haematology — bispecific FIXa/FX antibody; haemophilia A | CHF 4.5bn | ~2031+ | Bispecific antibody — not a P-gp substrate | No rationale. Haemophilia A is a coagulation disorder; elacridar mechanism not relevant | N/A | LOW | No opportunity |
| Alecensa alectinib |
Oncology — ALK inhibitor; ALK+ NSCLC (adjuvant and metastatic) | CHF 1.55bn | ~2028–2030 | NOT a P-gp substrate — explicitly confirmed in NEJM 2017 and preclinical studies. Alectinib was specifically engineered to evade P-gp efflux, which is the primary pharmacological basis for its CNS superiority over crizotinib (which IS a P-gp substrate). This design choice made Alecensa the standard of care for ALK+ NSCLC | No rationale — and an important cautionary benchmark. Alectinib's competitive advantage was achieved by designing AROUND P-gp. This history is the precise pharmacological context in which to pitch elacridar: "Roche already understands the clinical consequence of P-gp substrate status — Alecensa proved it. Now let us show you what happens when you apply this insight to your other small molecules that still face P-gp efflux." Use Alecensa as the educational opening in any Roche meeting | N/A | LOW | No opportunity (already P-gp non-substrate by design) |
| Xolair omalizumab |
Immunology — anti-IgE mAb; asthma, CSU, food allergy | CHF 2.5bn | ~2027–2028 | Monoclonal antibody — not a P-gp substrate | No rationale | N/A | LOW | No opportunity |
| Actemra / RoActemra tocilizumab |
Immunology — anti-IL-6R mAb; RA, GCA, CRS, sJIA | CHF ~1.1bn | Biosimilar pressure ongoing | Monoclonal antibody — not a P-gp substrate | No rationale | N/A | LOW | No opportunity |
| Fenebrutinib STAR RG7845 — Phase III |
Pipeline — non-covalent BTK inhibitor; relapsing MS + primary progressive MS (Phase III) | Pre-revenue | N/A — new asset (~2040+) | Small-molecule BTK inhibitor. Phase 2 (FENopta) data: mean CSF concentration 43.1 ng/mL after 12 weeks, exceeding IC90 for B cells and microglia (~65 nM). Brain penetrant but comparative BTK pharmacology studies rank tolebrutinib above fenebrutinib for absolute CNS penetrance — suggesting P-gp/BCRP may still limit fenebrutinib's maximum achievable CNS concentration | HIGH-PRIORITY PIPELINE COMBINATION. Fenebrutinib's key differentiation from tolebrutinib (Sanofi) is safety (non-covalent, reversible; no covalent off-target toxicity) rather than CNS penetrance. Tolebrutinib achieves higher CSF levels. An elacridar-enhanced fenebrutinib achieving CSF levels equal to or exceeding tolebrutinib would eliminate tolebrutinib's only pharmacological advantage while retaining fenebrutinib's superior safety profile. In PPMS specifically — where CNS-compartmentalised B cells and microglia drive irreversible disability accumulation — higher CNS BTK occupancy most plausibly translates to slowed progression. Phase 3 PPMS data reads out 2025–2026; if fenebrutinib shows a borderline PPMS signal, elacridar dose-optimisation could rescue the indication with enhanced CNS exposure. This is a high-value pipeline rescue and lifecycle innovation play | BOTH | HIGH | CHF 400m–1.0bn incremental (MS market CHF 20bn+; fenebrutinib peak sales est. CHF 3–5bn; CNS-enhanced version could own progressive MS sub-segment; ~50k PPMS patients in US+EU) |
| Giredestrant RG6171 — Phase III |
Pipeline — oral SERD; ER+/HER2- breast cancer (Phase III, positive data 2025) | Pre-revenue | N/A | Oral non-steroidal SERD. Detailed transporter substrate data not yet publicly available. Oral SERDs as a class can have P-gp sensitivity; fulvestrant (IV SERD predecessor) has poor oral bioavailability due partly to efflux. Giredestrant's excellent Phase 3 oral bioavailability in systemic disease suggests P-gp may not dominate, but CNS penetration in brain mets is uncharacterised | If giredestrant has any P-gp/BCRP sensitivity at the BBB (plausible for this molecular class), elacridar could enable CNS ER degradation for the first time — potentially the first oral SERD with proven brain metastasis activity. Most compelling as an addition to the inavolisib + elacridar breast cancer brain met programme: inavolisib + giredestrant + elacridar for ER+/PIK3CA+ brain mets would be a triple combination targeting two drivers of CNS metastasis simultaneously. Requires giredestrant transporter characterisation from Phase 3 PK studies | EFFICACY UP | MEDIUM | CHF 200–500m (HR+ brain mets if transporter data supportive; most valuable as add-on to inavolisib + elacridar regimen) |
| Divarasib RG6099 — Phase II/III |
Pipeline — KRAS G12C inhibitor; NSCLC, CRC | Pre-revenue | N/A | KRAS G12C inhibitor small molecule. Class precedent: sotorasib (Amgen, same class, same target) is a confirmed P-gp substrate with restricted brain penetration documented in published pharmacology. Structural analogy makes divarasib P-gp sensitivity likely, pending direct characterisation | KRAS G12C mutations occur in ~3% of primary brain tumours and in a meaningful fraction of NSCLC brain metastases. No approved targeted therapy for KRAS+ brain metastases exists. Divarasib + elacridar could be the first KRAS G12C inhibitor-based therapy for CNS disease. First step: characterise divarasib transporter substrate status; then run orthotopic KRAS G12C+ brain met mouse model. The class precedent from sotorasib makes this a testable and plausible hypothesis | EFFICACY UP | MEDIUM | CHF 200–400m (KRAS+ brain mets; niche but high-unmet need; possible orphan/breakthrough designation) |
| CT-388 / CT-996 GLP-1/GIP dual agonists — Phase II (Carmot) |
Pipeline — dual GLP-1/GIP agonists; obesity and T2D | Pre-revenue | N/A — new class | Novel GLP-1/GIP agonists (Carmot acquisition 2024). Transporter substrate status not yet published. If oral formulations are pursued, P-gp sensitivity could limit bioavailability — but injectable formulations bypass this entirely | Only relevant if CT-388/996 are being developed as oral formulations. Monitor Phase 2 PK readouts for transporter substrate signals; low priority until ADME data available | EFFICACY UP | LOW | Speculative — conditional on ADME data and oral formulation strategy |
| Tiragolumab anti-TIGIT mAb — Phase III |
Pipeline — anti-TIGIT checkpoint antibody; NSCLC, HCC, ESCC | Pre-revenue | N/A | Monoclonal antibody — not a P-gp substrate | No rationale | N/A | LOW | No opportunity |
| Trontinemab anti-amyloid mAb + TfR1 — Phase I/II AD |
Pipeline — transferrin receptor-assisted anti-amyloid-b mAb; Alzheimer's disease | Pre-revenue | N/A | Engineered mAb using transferrin receptor transcytosis for BBB crossing — not a P-gp substrate. A completely different CNS delivery paradigm | No P-gp rationale. Trontinemab uses receptor-mediated transcytosis — a parallel but separate CNS delivery technology to elacridar. No combination opportunity; however, this demonstrates Roche's strategic commitment to solving BBB access in CNS diseases — exactly the narrative in which to position our elacridar platform | N/A | LOW | No opportunity (different CNS delivery paradigm) |
| Vabysmo faricimab |
Ophthalmology — dual Ang-2/VEGF bispecific; nAMD, DME, DR | CHF 3.9bn | ~2033+ | Bispecific antibody, intravitreal injection — not a P-gp substrate. Delivered directly into the vitreous | No rationale. Intravitreal delivery bypasses all oral bioavailability and BBB considerations entirely | N/A | LOW | No opportunity |
| PiaSky crovalimab |
Haematology — anti-C5 mAb; PNH, aHUS, SCD | CHF ~200m (early launch) | ~2035+ | Monoclonal antibody — not a P-gp substrate | No rationale | N/A | LOW | No opportunity |
| Activase / TNKase alteplase / tenecteplase |
Cardiovascular — thrombolytics; ischaemic stroke, PE, STEMI | CHF 1.2bn | Biosimilar pressure | Protein biologics — not P-gp substrates. IV administration | No rationale | N/A | LOW | No opportunity |
| MabThera / Rituxan rituximab |
Haematology/Immunology — anti-CD20 mAb; B-cell malignancies, RA | CHF 1.38bn | Biosimilar-eroded globally | mAb — not a P-gp substrate | No rationale. Declining biosimilar-eroded asset | N/A | LOW | No opportunity |
LEAD PROGRAMME | ONCOLOGY | BREAST CANCER BRAIN METASTASES | PI3Ka INHIBITION + COMPLETE BBB TRANSPORTER BLOCKADE
The FDA label is the ultimate evidence — no inference required. The prescribing information for Itovebi (inavolisib), approved by the FDA in October 2024, explicitly states that inavolisib is a substrate of both P-glycoprotein and BCRP. This is the highest possible level of confirmatory evidence for an elacridar combination opportunity. There is no need for preclinical inference or structural analogy — the regulatory agency has already characterised the transporter profile. Roche's own clinical pharmacology team knows this. What they may not have considered is the clinical implication for brain metastases.
PIK3CA mutations are specifically enriched in breast cancer brain metastases. Published data (JCO Precision Oncology, 2020) show that in 307 patients with ER+/HER2- metastatic disease, brain metastases occurred significantly more often in PIK3CA-mutated tumours (30.8% vs 17.1%; P=0.005). This means inavolisib's approved patient population is precisely the group at highest risk for CNS spread. And yet inavolisib cannot adequately treat those brain lesions because P-gp/BCRP at the BBB effluxes it out before it can inhibit PI3Ka in brain tumour cells. The approved drug and the unmet indication are pharmacologically separated by exactly one mechanism that elacridar addresses.
Preclinical proof of principle already exists. Data presented at ASCO 2025 confirmed that inavolisib monotherapy and combination with anti-PD-1 reduced intracranial tumour size in orthotopic breast cancer brain metastasis mouse models, with combinations significantly extending overall survival. The biology works — the limiting factor is CNS drug exposure. Elacridar solves the exposure problem without altering the biology.
Inavolisib is already approved — this is a line extension, not a new drug. The combination product uses an already-characterised, already-approved active ingredient. Roche does not need to conduct a new safety programme for inavolisib itself. The development pathway is: Phase Ib DDI study (inavolisib + elacridar in patients) to confirm exposure enhancement and safety; Phase 2 in breast cancer brain met patients enriched for PIK3CA mutation (intracranial ORR as primary endpoint); accelerated FDA approval on Phase 2 data. Total development timeline from IND: approximately 3–4 years. This is the fastest clinical path of any programme in our series.
No competitor can replicate this combination. Alpelisib (Novartis, approved PIK3CA inhibitor) showed no significant brain distribution in intact-BBB preclinical animal models. Buparlisib (pan-PI3K inhibitor) had CNS penetration but caused intolerable psychiatric adverse effects from non-selective PI3K-beta and PI3K-delta CNS inhibition — the exact toxicity that inavolisib's PI3Ka selectivity avoids. The combination of (1) alpha-selective PI3K inhibition avoiding CNS psychiatric toxicity, and (2) elacridar-enabled BBB penetration, is a pharmacological combination that no competitor drug has or can achieve. This is a durable and defensible competitive moat.
Roche Diagnostics closes the loop. The combination requires a companion diagnostic: PIK3CA mutation testing (already approved for inavolisib — the VENTANA PIK3CA assay is FDA-cleared) and potentially P-gp expression testing to select patients most likely to benefit from elacridar. Roche Diagnostics already owns the PIK3CA companion diagnostic infrastructure. They can extend this to include P-gp expression. A fully integrated Roche therapeutic + diagnostic combination is uniquely achievable with this partner and not with any other company in our series.
Fenebrutinib is Roche's most important neurology pipeline asset — a Phase 3 non-covalent BTK inhibitor for both relapsing and primary progressive MS with strong Phase 2 and Phase 3 signals emerging through 2025/2026. Its key differentiation from tolebrutinib (Sanofi) is safety: non-covalent reversible binding avoids covalent off-target toxicity. But comparative BTK inhibitor pharmacology places tolebrutinib above fenebrutinib for CNS penetrance. An elacridar-enhanced formulation could close this gap and surpass tolebrutinib's CSF levels while retaining fenebrutinib's safety advantage — establishing it as the BTK inhibitor with both best CNS penetration AND best safety. PPMS, where CNS-compartmentalised microglia and B cells drive irreversible disability, is the sub-indication where maximum CNS BTK occupancy most plausibly translates to slowed progression. If Phase 3 PPMS data shows borderline efficacy, elacridar-enhanced fenebrutinib may rescue and differentiate this crucial indication.
Projected incremental sales: CHF 400m–1.0bn (PPMS sub-franchise) | N/A LOE (new asset, 15+ yr runway)
Polivy (CHF 1.1bn, +39% in 2024) carries an MMAE payload — a confirmed P-gp substrate. After ADC internalisation and linker cleavage in DLBCL cells, intracellular P-gp efflux reduces free MMAE concentration below the cytotoxic threshold in P-gp-overexpressing cells. This is a well-documented mechanism of acquired ADC resistance for auristatin-payload drugs. Elacridar co-administration would inhibit intracellular P-gp efflux, restoring MMAE cytotoxicity. The companion diagnostic (P-gp IHC at progression biopsy) identifies the MDR-driven resistant subgroup (~30% of progressors). This creates a precision oncology second-line strategy with a clear biomarker. Roche Diagnostics can develop and commercialise both the P-gp companion test and the Polivy combination — a fully integrated Roche platform play within their existing DLBCL franchise.
Projected incremental sales: CHF 300–600m | LOE ~2032 | In vitro P-gp data needed before clinical
Divarasib (Phase 2/3) is Roche's KRAS G12C inhibitor. The class precedent is clear: sotorasib (Amgen, same class), is a confirmed P-gp substrate with restricted brain penetration. If divarasib shares this class pharmacology — likely given structural relationships within KRAS G12C inhibitors — elacridar could enable CNS penetration for KRAS G12C+ brain metastases from NSCLC and CRC. There is no approved targeted therapy for KRAS+ brain metastases. The first KRAS inhibitor + elacridar combination demonstrating intracranial activity would gain Breakthrough Therapy Designation and accelerated approval. Estimated 3,000–5,000 patients per year in US+EU with KRAS G12C+ NSCLC brain metastases represent an orphan-eligible, high-pricing niche.
Projected incremental sales: CHF 200–400m | Pipeline asset | Divarasib transporter characterisation required first
Giredestrant (Phase 3, positive data 2025) is Roche's oral SERD. ER+ breast cancer brain metastases retain ER positivity in ~80% of cases — making ER degradation a rational CNS target. If giredestrant has P-gp/BCRP sensitivity at the BBB (transporter data pending from Phase 3 PK studies), elacridar co-administration could enable CNS oestrogen receptor degradation — potentially the first oral SERD with proven brain met activity. Most powerful as a triplet with inavolisib + elacridar, targeting both PI3Ka and ER in PIK3CA+ HR+ brain metastases simultaneously. This triple combination (giredestrant + inavolisib + elacridar) would be mechanistically the most comprehensive anti-tumour regimen for this indication. Conditional on giredestrant transporter characterisation data.
Projected incremental sales: CHF 200–500m (if transporter data supportive) | Conditional on Phase 3 PK data
| Priority | Combination | Indication | Mechanism | Current Drug Sales | Projected Combo Peak | LOE | Development Readiness |
|---|---|---|---|---|---|---|---|
| STAR STAR 1 — LEAD | Inavolisib + Elacridar | PIK3CA+ Breast Cancer Brain Metastases | BBB penetration: P-gp/BCRP confirmed in FDA label; CNS PI3Ka inhibition unlocked; preclinical brain met efficacy data at ASCO 2025 | Pre-revenue (Oct 2024 launch) | CHF 1.5–2.5bn | ~2033+ | FDA label confirms substrate; ASCO 2025 brain met data exists; ready for Phase Ib DDI study |
| STAR 2 | Fenebrutinib + Elacridar | Primary Progressive MS — enhanced CNS BTK inhibition | Optimise already-demonstrated CNS penetration (43.1 ng/mL CSF); surpass competitor CNS levels; rescue borderline PPMS signal | Pre-revenue (Phase III) | CHF 400m–1.0bn | N/A (15+ yr runway) | CSF concentration published; transporter characterisation of fenebrutinib needed; Phase Ib design ready pending data |
| 3 | Polivy + Elacridar | P-gp-overexpressing Polivy-resistant DLBCL | MMAE intracellular efflux reversal in MDR-driven resistant tumours; companion dx selection | CHF 1.1bn (+39%) | CHF 300–600m | ~2032 | In vitro P-gp efflux of MMAE data; Roche Diagnostics companion dx co-development opportunity |
| 4 | Divarasib + Elacridar | KRAS G12C+ Brain Metastases (NSCLC primary) | BBB penetration enhancement (class precedent from sotorasib substrate data); no competing KRAS CNS therapy | Pre-revenue (Phase II/III) | CHF 200–400m | N/A — pipeline | Divarasib transporter characterisation required; sotorasib class analogy supportive |
| 5 | Giredestrant + Elacridar | HR+ Breast Cancer Brain Mets (CNS SERD) — add-on to inavolisib combination | BBB penetration enhancement for oral SERD; most valuable as triplet with inavolisib + elacridar | Pre-revenue (Phase III) | CHF 200–500m | N/A — pipeline | Conditional on giredestrant transporter characterisation from Phase 3 PK data |